Investors

Koshy Associates is building a network of investors at all levels from angels and high net worth individuals to VC and PE investment firms.

If you would like to be kept in the loop on potential investment opportunities, then please contact Paul Koshy via LinkedIn or fill in the contact form on this website.

We can schedule in a call, as appropriate, to get to know one another and to understand your current priorities, your investment criteria and amounts, to allow us to send you the most relevant leads.

In the meantime, please do look at some current investment opportunities listed below.

Please Note: The work undertaken by Koshy Associates cannot be construed as investment advice. Koshy Associates conducts its work with both investors and innovators on a non-advisory basis, and both investors and innovators are responsible to conduct their own due diligence.

Examples of investment-raising projects

Scotland

A disruptor in the funeral plans sector. With only 6% of adults with a funeral plan (vs. 68% in Holland), the UK market is ripe for disruption. Product-market fit and digital added-value elements, combines with an innovative business model and route to market. Soft launched Q1 2022. Seeking £500K to £1M investment, for 1.5% per £100K; minimum investment £25K. EIS advance assurance. Dividend payouts from year 3 onwards. Targeting an exit in 5 years with an expected 10 to 20-fold investor return, based on market comparators. Pitch deck available upon request.

London

Automated ESG assessments: An AI and NLP-powered SaaS platform delivering automated ESG and operational resilience assessments. Supporting sustainability and survivability – reducing risk and cost of innovation adoption and risk in the supply chain. £6bn+ TAM. Revenue generating. Traction in finance, investment and energy sectors, including significant partnerships with industry bodies; applicable across all sectors. Current seed round: £360K already banked. Seeking remaining £440K. EIS advance assurance. Preparing for Series A in 2023. Forecasted EBITDA: £12M in 2025. Multiple, clearly defined exit opportunities. Pitch deck available upon request.

London

Premium nutritional supplement brand, targeting the growing health conscious, vegan-leaning, environmentally-friendly market. Existing consumer preferences towards nutritional supplements and functional food & drink products substantially accelerated by COVID-19. Soft launched in 2022 with nutraceuticals and juice health shots. Supporting personalised nutrition. Ethically sourced ingredients, plastic-free packaging, UK manufactured. B2B and B2C channels. First brand ambassador onboard. Seeking £150K for 10% of the business, with SEIS advance assurance. Forecasting a 10 to 15-fold investor return by end of year 5. Strategic buyers and PE firms active in acquiring supplement and functional food brands. Pitch deck available upon request.

Oxfordshire

An online platform and hyper-local delivery service connecting consumers to their existing local independent food suppliers. Customers increasingly want to shop locally and know the provenance of their food. At the same time online grocery shopping and home delivery is gaining traction. Yet only 26% of the UK’s 19,000 local independent food retailers have a digital presence. Local independent retailers generate £10bn of sales (serviceable obtainable market). This service enables customers to place their order from multiple, local stores on a single platform, and receive their order in a single, convenient delivery. Serving underserved, edge-of-urban/semi-rural locations with a strong population catchment area. Seeking £300k for 15% of the business. £94k already committed. SEIS eligible, EIS pending.

London

A specialist firm in the largely untapped Withholdings Tax Recovery industry. Withholding Taxes are applied to foreign investment income, but due to Double Taxation agreements a large portion of this taxation can be reclaimed. An estimated unclaimed withholding tax recovery of $10 billion per year, in the EU alone. Global client types: family offices; asset managers; wealth managers; hedge funds; HNWIs; pension funds; international corporations. Seeking £300K SEIS and EIS, to capitalise on current traction and client pipeline. Minimum investment £5K. Conservative projection of 40-fold growth in 7 years, to approx. £40m valuation. Targeting exit via acquisition by large asset management firms, active in the M&A space. Pitch deck available upon request.

Yorkshire

A developer of a wearable delivering anxiety relief at the point of need. Developed with input from academics, therapists and anxiety sufferers. Pre-revenue. Seeking £95K to finalise prototype for further end-user testing. EIS advance assurance being sought. Clear roadmap to market including a product launch in Q2 2022. Projecting revenue in the region of £14m in 2026. Pitch deck available upon request.

London

UK-incorporated R&D Pharma company, established to repurpose and commercialise an FDA-approved compound. This venture was launched based on early data showing therapeutic potential in treating auto-Immune diseases and cancers. In the 6 years the Company has been investigating the drug, their research has led to the filing of 23 proprietary patent applications globally across a range of therapeutic areas as a stand-alone agent, as well as an adjuvant to other treatments. The Company is currently targeting one percent of an 8 billion-dollar market and then over 5 to 10 years grow that to thirty percent of the market. The company’s board includes recognised and experienced medical, regulatory and business development specialists with experience with a track record in scaling businesses. Impressive Phase I results are soon to be released.

The Company is selling $1.5M of its remaining £10M shares available at its Phase I valuation, prior to commencing its Phase II raise at a 5-fold increase in valuation. Investment documents available upon request.

USA

Specialist VC, investing in early-stage Augmented Intelligence. Augmented Intelligence is the subset of robotics and AI that focuses on human with machine, rather than human vs machine.

Having raised $15M of its targeted $20M fund, this VC is seeking $5M (up to $10M) in additional LP funding.

This VC is targeting a five-fold return or better on Partner’s capital over a 5-10 year window in an ESG compliant manner.

The Fund’s leadership worked in executive commercial roles at Carnegie Mellon’s Robotics Institute, the National Robotics Engineering Center, Citrix, The Citrix Startup Accelerator, and Autodesk Reality Capture. Their collective work has been recognised in many forums, including IEEE, Davos, The Global Manufacturing and Industrialisation Summit, AI for Good, and the United Nations General Assembly.

RH invests $100K-$5M in staged investments in early stage Augmented Intelligence companies. The approach is to be deeply involved with each company, during early assessment and company shaping, and during the initial development of the business. Further information available upon request.

Africa / USA

A VC firm investing capital, capacity and community in high-growth African tech ready to scale up. The Fund is structured to deliver a risk adjusted return of 29% net IRR over ten years.

Investment focus: Digital-economy themes, including fintech, edtech, clean tech, and agtech.

Track record: This VC achieved a 10-fold growth in 5 years with its prior Startup fund.

Partners/advisors and offices in Africa and USA.

This VC is seeking LPs to partner with them on this $50M to $100M African high-growth tech fund. One Pager available upon request.